Xalkori Approved For Rare Genetic Form of Lung Cancer
by Scott Roberts, Mar 11, 2016 at 2:34 PM • FDA Approvals
ROS-1 positive NSCLC
by Scott Roberts, Mar 11, 2016 at 2:34 PM • FDA Approvals
ROS-1 positive NSCLC
by E.J. Mundell, Mar 4, 2016 at 9:00 AM • News
Study suggests link for regimens rich in refined carbs, potatoes, but it can't prove cause-and-effect
by Dennis Thompson, HealthDay Reporter, Feb 29, 2016 at 4:00 PM • News
Suffering can escalate for those with two months of reserves or less, study finds
by Steven Reinberg, HealthDay Reporter, Feb 22, 2016 at 4:00 PM • News
But black women still more susceptible to breast cancer, black men to colon cancer
by Robert Preidt, Feb 22, 2016 at 4:00 PM • News
Study finds using costly test as first option for follow-up may not improve survival
by Dennis Thompson, HealthDay Reporter, Feb 22, 2016 at 2:00 PM • News
Using targets from recent Paris Agreement, scientists calculate potential deaths averted from heart, lung disease
by E.J. Mundell, Feb 12, 2016 at 12:00 PM • News
Study finds cola boosts effectiveness of Tarceva for patients who are also taking a heartburn medicine
by Robert Preidt, Jan 26, 2016 at 9:00 AM • News
Study found the very thin or very obese had the highest odds for complications
by Mary Elizabeth Dallas, Jan 25, 2016 at 12:00 PM • News
Intervention helped boost success rates a bit, even when counseling wasn't included, study found
by Steven Reinberg, HealthDay Reporter, Jan 19, 2016 at 12:00 PM • News
Doctors need to heed preferences of patients, prepare for end of life sooner, experts say
by Mary Elizabeth Dallas, Jan 14, 2016 at 2:00 PM • News
Chest scans a cost-effective strategy to screen this population, researchers say
by Robert Preidt, Jan 14, 2016 at 2:00 PM • News
Though incidence lower than among white Americans, researchers say
by Kathleen Doheny, HealthDay Reporter, Jan 7, 2016 at 12:00 PM • News
That translates to an additional 1.7 million survivors, expert says
by Dennis Thompson, HealthDay Reporter, Dec 21, 2015 at 9:00 AM • News
Tumor location, type of treatment unlikely to influence decision
by Robert Preidt, Dec 21, 2015 at 7:00 AM • News
In study, the immune-based therapy beat an older drug with fewer side effects, but it's expensive
Get the latest health news & tips via email, Mon‑Fri: